Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

References

• Alimta (pemetrexed) injection [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2013
   Google Scholar
• Sørensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011;7:919-28
   PubMed Web of Science ®Google Scholar
• Glezerman IG, Pietanza MC, Miller V, et al. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 2011;58:817-20
   PubMed Web of Science ®Google Scholar
• Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 2006;26:641-54
   PubMed Web of Science ®Google Scholar
• Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-62
   PubMed Web of Science ®Google Scholar
• Finkel KW, Howard SC. Onco-nephrology: an invitation to a new field. J Clin Oncol 2014;32:2389-90
   PubMed Web of Science ®Google Scholar
• Lindeman RD. Changes in renal function with aging. Implications for treatment. Drugs Aging 1992;2:423-31
   PubMed Web of Science ®Google Scholar
• Musso CG, Liakopoulos V, Ioannidis I, et al. Acute renal failure in the elderly: particular characteristics. Int Urol Nephrol 2006;38:787-93
   PubMed Web of Science ®Google Scholar
• Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006;2:80-91
   PubMedGoogle Scholar
• Rombolà G, Vaira F, Trezzi M, et al. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage. J Nephrol 2015;28:187-91
   PubMed Web of Science ®Google Scholar
• Pujol JL, Paz-Ares L, de Marinis F, et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2014;15:418-25
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-902
   PubMed Web of Science ®Google Scholar
• Langer CJ, Paz-Ares LG, Wozniak AJ, et al. Safety analyses of pemetrexed–cisplatin and pemetrexed maintenance therapies in patients with advanced non-squamous NSCLC: retrospective analyses from 2 phase III studies. Clin Lung Cancer 2017;18:489-96
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-55
   PubMed Web of Science ®Google Scholar
• Gridelli C, de Marinis F, Pujol JL, et al. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2012;7:1713-21
   PubMed Web of Science ®Google Scholar
• Kutluk Cenik B, Sun H, Gerber DE. Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer 2013;80:326-32
   PubMed Web of Science ®Google Scholar
• Gridelli C, de Marinis F, Thomas M, et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol 2014;9:991-7
   PubMed Web of Science ®Google Scholar
• Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int 2015;87:909-17
   PubMed Web of Science ®Google Scholar
• Chauvet S, Courbebaisse M, Ronco P, et al. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol 2014;82:402-6
   PubMed Web of Science ®Google Scholar
• Vootukuru V, Liew YP, Nally JV Jr. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 2006;23:419-22
   PubMed Web of Science ®Google Scholar
• Michels J, Spano JP, Brocheriou I, et al. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol 2009;2:53-6
   PubMedGoogle Scholar
• Castro M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol 2003;21:4066-9
   PubMed Web of Science ®Google Scholar
• Porta JM, Vicente de Vera Floristán C, Inglán PB, et al. Acute renal failure associated with Pemetrexed (Alimta) [in Spanish]. Nefrologia 2009;29:610-11
   PubMed Web of Science ®Google Scholar
• Zattera T, Londrino F, Trezzi M, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review. J Nephropathol 2017;6:43-8
   PubMedGoogle Scholar
• Charlton P, Karapanagiotou E, Montes A, et al. Discontinuation of maintenance pemetrexed (mPEM) in non-small cell lung cancer (NSCLC) due to renal failure. Lung Cancer 2015;87:S24(abstr 60)
   Web of Science ®Google Scholar
• Pyeritz RE. Letter: creatinine clearance and age. Ann Intern Med 1976;85:534-6
   PubMedGoogle Scholar
• Mennecier B, Bigay-Game L, Corre R, et al. Maintenance with pemetrexed in lung cancers: how to optimize the long-term management of patients [in French]? La Lettre du Cancérologue 2014;23:344-9
   Google Scholar
• Chen CY, Lin JW, Huang JW, et al. Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2015;16:e131-40
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (US). Chemotherapy and you: support for people with cancer. (NIH publication no. 11-7156). Bethesda (MD): US Department of Health and Human Services, 2011
   Google Scholar
• Oka T, Kimura T, Suzumura T, et al. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study. BMC Pharmacol Toxicol 2014;15:70
   PubMed Web of Science ®Google Scholar
• Sassier M, Dugué AE, Clarisse B, et al. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer 2015;89:161-6
   PubMed Web of Science ®Google Scholar